Following recent FDA approval of two renal denervation systems for the treatment of hypertension, experts speculate on which patients will be prioritized for the procedure.
An overview of the journey and significant events of 2023 that have catapulted semaglutide from a type 2 diabetes agent to the topic of discussions among circles across healthcare and beyond.
This installment in our Unprevented series examines the growing impact of chronic kidney disease on public health and what those in the field are doing to mitigate this growing crisis.